BlueCrest Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

BlueCrest Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,822	Closed	-$213K	–	566
2019 Q3	$213K	Buy	+2,822	New	+$333K	0.01%	477
2019 Q2	–	Sell	-16,647	Closed	-$1.98M	–	974
2019 Q1	$1.98M	Buy	+16,647	New	+$2.14M	0.08%	178
2018 Q4	–	Sell	-16,819	Closed	-$2.72M	–	1374
2018 Q3	$2.72M	Sell	16,819 -41,810	-71%	-$5.72M	0.07%	198
2018 Q2	$7.75M	Buy	58,629 +54,220	+1,230%	+$5.11M	0.2%	105
2018 Q1	$327K	Buy	+4,409	New	+$294K	0.01%	1000
2016 Q4	–	Sell	-8,232	Closed	-$506K	–	862
2016 Q3	$506K	Buy	+8,232	New	+$249K	0.02%	526

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlueCrest Capital Management's SRPT Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 2,822 shares — an estimated $213K sold.

BlueCrest Capital Management first reported a position in SRPT in Q3 2016 and held it in 6 quarters. The position peaked at $7.75M in Q2 2018. 389 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

BlueCrest Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
BlueCrest Capital Management sold 2,822 Sarepta Therapeutics shares in Q4 2019, an estimated $213K.
BlueCrest Capital Management first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 6 quarters.
BlueCrest Capital Management's Sarepta Therapeutics position peaked at $7.75M in Q2 2018.
389 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.